AbbVie (ABBV) Wins A New Lymphoma Nod, Is The Stock Still Cheap?
AbbVie (ABBV) Wins A New Lymphoma Nod, Is The Stock Still Cheap? simplywall.st
Covered in this story
What has happened since
- AbbVie is up 1.1% since this was published, 2 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 52 stories mentioning AbbVie, the earliest published 19 Mar 2026.
Summary aggregated from simplywall.st's public RSS feed. The full reporting belongs to simplywall.st — please read it on their site.